Drug Profile
STA 36
Alternative Names: STA36Latest Information Update: 22 Jul 2015
Price :
$50
*
At a glance
- Originator SunTen Phytotech
- Developer Lumosa Therapeutics
- Class Antiasthmatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Allergic asthma
Most Recent Events
- 22 Jul 2015 Discontinued - Phase-II for Allergic asthma (Adjuvant therapy) in Taiwan (unspecified route)
- 31 Jan 2008 Taiwan Department of Health approves IND application for STA 36 in asthma
- 12 Jul 2006 Phase-II clinical trials in Allergic asthma (Adjuvant therapy) in Taiwan (unspecified route)